logo_ProQR-150x150.png
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
January 07, 2021 07:00 ET | ProQR Therapeutics N.V.
Top-line results expected H1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands...